NTRA Earnings

NTRA reported its FY2025Q4 earnings on 2026-02-26, showcasing a revenue of 0.00 against an estimate of 565.00M, resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.46 by 0% . The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following NTRA's FY2025Q4 earnings announcement on 2026-02-26, the stock price moved by % on the day of the release. Over the subsequent five days, it saw a % change. Historically, NTRA's stock price tends to shift by an average of -1.21% in the 10 days leading up to earnings and +11.97% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate NTRA’s annual revenue to reach 577.00M, while the EPS is projected at 0.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 6.04% and EPS estimates Revise Upward by 7.37% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between NTRA's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Upward by 6.04%, while EPS estimates moved Revise Upward by 7.37% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, NTRA's stock price typically moves by -1.21% in the 10 days before its earnings and +11.97% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 0.00 and revenue of 577.00M.

The earnings call highlights several positive factors: raised revenue and gross margin guidance, strong cash flow expectations, and strategic investments in new product launches and clinical trials. Despite some vague responses in the Q&A, the overall sentiment is positive due to optimistic guidance, Medicare reimbursement expansion, and AI-driven efficiencies. The raised guidance and strong financial metrics, coupled with the positive outlook for future growth, suggest a likely positive stock price movement over the next two weeks.